News Sentiment

PAVM sentiment intelligence

PAVmed Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 5.60 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

74/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-1.9% over one week, +12.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to book forward of PAVmed Inc. – NASDAQ:PAVM

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 74/100 classification
One-week reaction -1.9% Price digesting
Trend fit Trend inactive 12.0% over four weeks
Fair value -86.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 43
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 12
Market source 11
TradingView 8
PR Newswire 4
Stock Titan 3
StockStory 2
Intellectia AI 2
Motley Fool 2

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 23
Analyst action 6
Deals and strategy 3
Balance sheet 2
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
TradingKey Direct company coverage

PAVM|PAVmed Inc|Price:6.390|Chg%:0.04

PAVmed Inc (PAVM) shows stable fundamentals, industry-leading ESG disclosure, and high growth potential, though its valuation is only fairly valued within its industry. Analyst ratings are "Buy" with a target price of $40.50, despite recent weak market performance. The company sp

Tone
Neutral 50/100
Event
Analyst action
Published
22 May 2026 12:08
Source
TradingKey
Investing.com India Direct company coverage

Earnings call transcript: PAVmed Q1 2026 sees restructuring gains

PAVmed Inc. (PAVM) reported mixed financial results for Q1 2026, featuring significant capital structure improvements from a recent recapitalization despite a stock decline. The company is actively relaunching its medical device portfolio, pursuing new assets, and advancing its s

Tone
Neutral 50/100
Event
Earnings
Published
20 May 2026 23:11
Source
Investing.com India
Stock Titan Direct company coverage

PAVmed Q1: cancer test and implantable monitor push toward coverage, FDA

PAVmed reported Q1 2026 financial results with a GAAP net loss of $7.0 million, and non-GAAP adjusted net loss of $1.9 million, while cash and equivalents increased to $6.5 million. The company's subsidiary, Lucid Diagnostics, generated $1.3 million in EsoGuard revenue and secure

Tone
Neutral 50/100
Event
Earnings
Published
19 May 2026 06:40
Source
Stock Titan